Autopsy report · NCT04067492
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack
Cause of deathSlow enrollment, also staffing, sites or logistics
“In view of the continuing insufficient patient recruitment in the study due to the difficult epidemiological situation and the need for rational allocation of company resources, as well as based on the results of the interim analysis.”
Life of this trial
- Registered 1 year 4 months after it had already started.
- Ran for about 2 years 2 months before it stopped.
- 47 participants enrolled.
- Results were posted on the registry 2 years 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- R-Pharm
- Sponsor type
- Industry
- Conditions
- Gout Attack
- Interventions
- RPH - 104; Voltaren®
- Participants
- 47
- Sites
- 11
- Countries
- Russia
Trials that died the same way
- Daptomycin in Pediatric Patients With Bacterial Meningitis
“Insufficient patient recruitment” - Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia
“Patient recruitment insufficient” - Fesoterodine on Urgency Episodes in Parkinson's Disease Population
“Insufficient or untimely patient recruitment” - Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency
“Insufficient recruitment of suitable patients.” - Vitamin D Levels In Patients Who Has Normal to Grade 2 Knee Arthroscopy Changes
“Lack of patients with recruitment criteria”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.